InsidersTradesSigma
Total declarations
Company
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
5
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the detailed record of transactions filed by HENWOOD GERALDINE, Chief Executive Officer. Director active across 1 company, notably Baudax Bio, Inc.. Aggregated, 10 filings have been published. Split: 5 buys · 0 sell. Total volume traded: €19k. History available since 7 May 2021. The latest transaction was filed on 15 December 2022 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations10 total
1,200 shares@ US$2.54768.1% of flowCommon StockSEC:0001062993-22-024038:0
Ideal exit: 11 Sept 2023 (T+270)
39,473 shares0Common StockSEC:0001062993-22-015123:0
18,636 shares@ US$0.3131.7% of flowCommon StockSEC:0000899243-21-049629
18,636 shares@ US$0.3115.8% of flowCommon StockSEC:0000899243-21-049629:0
9,155 shares@ US$0.358.7% of flowCommon StockSEC:0000899243-21-048181:0
9,155 shares@ US$0.3517.5% of flowCommon StockSEC:0000899243-21-048181
8,200 shares@ US$0.585112.7% of flowCommon StockSEC:0001192482-21-000728:0
Ideal exit: 19 Jun 2022 (T+270)
8,200 shares@ US$0.585111.6% of flowCommon StockSEC:0001192482-21-000728
Ideal exit: 19 Jun 2022 (T+270)
6,000 shares@ US$0.83212.8% of flowCommon StockSEC:0001192482-21-000407:0
Ideal exit: 1 Feb 2022 (T+270)
6,000 shares@ US$0.83212.8% of flowCommon StockSEC:0001192482-21-000407
Ideal exit: 1 Feb 2022 (T+270)
10 of 10 declarations
About HENWOOD GERALDINE
HENWOOD GERALDINE serves as President and CEO at Baudax Bio, Inc. She is responsible for the strategic direction of the company and the management of its daily operations. Under her leadership, Baudax Bio is committed to developing innovative treatments for patients. HENWOOD GERALDINE plays a crucial role in defining the company's vision and establishing strong relationships with investors and partners.
